;PMID: 8625450
;source_file_661.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)section:[e:44..99] = [t:44..99]
;2)section:[e:103..192] = [t:103..192]
;3)section:[e:196..242] = [t:196..242]
;4)section:[e:246..318] = [t:246..318]
;5)sentence:[e:322..583] = [t:322..583]
;6)sentence:[e:584..796] = [t:584..796]
;7)sentence:[e:797..1012] = [t:797..1012]
;8)sentence:[e:1013..1140] = [t:1013..1140]
;9)sentence:[e:1141..1385] = [t:1141..1385]
;10)sentence:[e:1386..1541] = [t:1386..1541]
;11)sentence:[e:1542..1679] = [t:1542..1679]
;12)sentence:[e:1680..1877] = [t:1680..1877]
;13)sentence:[e:1878..2017] = [t:1878..2017]
;14)section:[e:2021..2065] = [t:2021..2065]

;section 0 Span:0..38
;Carcinogenesis. 1996 Feb;17(2):277-82.
(SEC
  (FRAG (VBG:[0..14] Carcinogenesis) (RB:[14..15] .) (CD:[16..20] 1996)
        (IN:[21..26] Feb;1) (CD:[26..27] 7) (NN:[27..28] -LRB-) (NN:[28..29] 2)
        (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..33] 27)
        (CD:[33..37] 7-82) (.:[37..38] .)))

;section 1 Span:44..99
;Comment in:      Carcinogenesis. 1997 Jul;18(7):1435-6.
(SEC
  (FRAG (NNP:[44..51] Comment) (VBZ:[52..54] in) (DT:[54..55] :)
        (NNP:[61..75] Carcinogenesis) (IN:[75..76] .) (CD:[77..81] 1997)
        (CC:[82..87] Jul;1) (CD:[87..88] 8) (NN:[88..89] -LRB-) (NN:[89..90] 7)
        (NN:[90..91] -RRB-) (.:[91..92] :) (CD:[92..95] 143)
        (-RRB-:[95..98] 5-6) (.:[98..99] .)))

;section 2 Span:103..192
;CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent 
;sulforaphane.
;[103..109]:cyp450:"CYP2E1"
;[157..165]:substance:"broccoli"
;[179..191]:substance:"sulforaphane"
(SEC
  (NP-HLN
    (NP
      (ADJP (NN:[103..109] CYP2E1) (HYPH:[109..110] -) (VBN:[110..118] mediated))
      (NN:[119..128] mechanism))
    (PP (IN:[129..131] of)
      (NP
        (NP (AFX:[132..136] anti) (HYPH:[136..137] -)
            (NN:[137..149] genotoxicity))
        (PP (IN:[150..152] of)
          (NP
            (NP (DT:[153..156] the) (NN:[157..165] broccoli)
                (NN:[166..177] constituent))
            (NP (NN:[179..191] sulforaphane))))))
    (.:[191..192] .)))
;ERROR_Entity in section[103..109]:cyp450 "CYP2E1"
;ERROR_Entity in section[157..165]:substance "broccoli"
;ERROR_Entity in section[179..191]:substance "sulforaphane"

;section 3 Span:196..242
;Barcelo S, Gardiner JM, Gescher A, Chipman JK.
(SEC
  (FRAG (NNP:[196..203] Barcelo) (NNP:[204..205] S) (,:[205..206] ,)
        (NNP:[207..215] Gardiner) (NNP:[216..218] JM) (,:[218..219] ,)
        (NNP:[220..227] Gescher) (NNP:[228..229] A) (,:[229..230] ,)
        (NNP:[231..238] Chipman) (NNP:[239..242] JK.)))

;section 4 Span:246..318
;Department of Pharmaceutical Sciences, Aston University, Birmingham, UK.
(SEC
  (FRAG (NNP:[246..256] Department) (IN:[257..259] of)
        (NNP:[260..274] Pharmaceutical) (NNPS:[275..283] Sciences)
        (,:[283..284] ,) (NNP:[285..290] Aston) (NNP:[291..301] University)
        (,:[301..302] ,) (NNP:[303..313] Birmingham) (,:[313..314] ,)
        (NNP:[315..318] UK.)))

;sentence 5 Span:322..583
;The broccoli constituent sulforaphane
;(1-isothiocyanate-4-methylsulfinylbutane)  has previously been shown to
;protect rats against  9,10-dimethyl-1,2-benz[a]anthracene tumorigenesis,
;thought to be due, at least  in part, to induction of phase II
;detoxification.
;[326..334]:substance:"broccoli"
;[347..359]:substance:"sulforaphane"
;[361..400]:substance:"1-isothiocyanate-4-methylsulfinylbutane"
;[454..489]:substance:"9,10-dimethyl-1,2-benz[a]anthracene"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[322..325] The) (NN:[326..334] broccoli)
          (NN:[335..346] constituent))
      (NP
        (NP (NN:[347..359] sulforaphane))
        (NP (-LRB-:[360..361] -LRB-)
            (NN:[361..400] 1-isothiocyanate-4-methylsulfinylbutane)
            (-RRB-:[400..401] -RRB-))))
    (VP (VBZ:[403..406] has)
      (ADVP-TMP (RB:[407..417] previously))
      (VP (VBN:[418..422] been)
        (VP (VBN:[423..428] shown)
          (S
            (NP-SBJ-2 (-NONE-:[428..428] *))
            (VP (TO:[429..431] to)
              (VP (VB:[432..439] protect)
                (NP
                  (NP (NNS:[440..444] rats))
                  (PP (IN:[445..452] against)
                    (NP
                        (NN:[454..489] 9,10-dimethyl-1,2-benz-LSB-a-RSB-anthracene)
                        (NN:[490..503] tumorigenesis)))))))))
      (,:[503..504] ,)
      (S-ADV
        (NP-SBJ-1 (-NONE-:[504..504] *))
        (VP (VBN:[505..512] thought)
          (S
            (NP-SBJ-1 (-NONE-:[512..512] *))
            (VP (TO:[513..515] to)
              (VP (VB:[516..518] be)
                (PP-PRD (JJ:[519..522] due) (,:[522..523] ,)
                  (PP
                    (ADVP (IN:[524..526] at) (JJS:[527..532] least))
                    (IN:[534..536] in)
                    (NP (NN:[537..541] part)))
                  (,:[541..542] ,)
                  (PP (TO:[543..545] to)
                    (NP
                      (NP (NN:[546..555] induction))
                      (PP (IN:[556..558] of)
                        (NP
                          (NML (NN:[559..564] phase) (CD:[565..567] II))
                          (NN:[568..582] detoxification))))))))))))
    (.:[582..583] .)))

;sentence 6 Span:584..796
;We investigated the ability of  sulforaphane to also inhibit the phase I
;enzyme cytochrome P450 isoenzyme 2E1  (CYP2E1), which is responsible for
;activation of several carcinogens, including  dialkylnitrosamines.
;[616..628]:substance:"sulforaphane"
;[657..663]:substance:"enzyme"
;[664..693]:cyp450:"cytochrome P450 isoenzyme 2E1"
;[696..702]:cyp450:"CYP2E1"
;[752..763]:substance:"carcinogens"
;[776..795]:substance:"dialkylnitrosamines"
(SENT
  (S
    (NP-SBJ (PRP:[584..586] We))
    (VP (VBD:[587..599] investigated)
      (NP
        (NP (DT:[600..603] the) (NN:[604..611] ability)
          (S-2 (-NONE-:[611..611] *ICH*)))
        (PP (IN:[612..614] of)
          (NP (NN:[616..628] sulforaphane)))
        (S-2
          (NP-SBJ (-NONE-:[628..628] *))
          (VP (TO:[629..631] to)
            (ADVP (RB:[632..636] also))
            (VP (VB:[637..644] inhibit)
              (NP
                (NP
                  (NP (DT:[645..648] the)
                    (NML (NN:[649..654] phase) (CD:[655..656] I))
                    (NN:[657..663] enzyme))
                  (NP
                    (NP
                      (NML (NN:[664..674] cytochrome) (NN:[675..679] P450))
                      (NN:[680..689] isoenzyme) (NN:[690..693] 2E1))
                    (NP (-LRB-:[695..696] -LRB-) (NN:[696..702] CYP2E1)
                        (-RRB-:[702..703] -RRB-))))
                (,:[703..704] ,)
                (SBAR
                  (WHNP-1 (WDT:[705..710] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[710..710] *T*))
                    (VP (VBZ:[711..713] is)
                      (ADJP-PRD (JJ:[714..725] responsible)
                        (PP (IN:[726..729] for)
                          (NP
                            (NP (NN:[730..740] activation))
                            (PP (IN:[741..743] of)
                              (NP
                                (NP (JJ:[744..751] several)
                                    (NNS:[752..763] carcinogens))
                                (,:[763..764] ,)
                                (PP (VBG:[765..774] including)
                                  (NP (NNS:[776..795] dialkylnitrosamines)))))))))))))))))
    (.:[795..796] .)))

;sentence 7 Span:797..1012
;Using the p-nitrophenol hydroxylation assay in microsomes  from livers of
;acetone-treated Sprague-Dawley rats, sulforaphane was shown to be  a potent
;competitive inhibitor of CYP2E1 with a Ki of 37.0 +/- 4.5 microM.
;[807..820]:substance:"p-nitrophenol"
;[871..878]:substance:"acetone"
;[908..920]:substance:"sulforaphane"
;[959..968]:substance:"inhibitor"
;[972..978]:cyp450:"CYP2E1"
;[986..988]:quantitative-name:"Ki"
;[992..1004]:quantitative-value:"37.0 +/- 4.5"
;[1005..1011]:quantitative-units:"microM"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[797..797] *))
      (VP (VBG:[797..802] Using)
        (NP (DT:[803..806] the)
          (NML (NN:[807..820] p-nitrophenol) (NN:[821..834] hydroxylation))
          (NN:[835..840] assay))
        (PP-LOC (IN:[841..843] in)
          (NP
            (NP (NNS:[844..854] microsomes))
            (PP (IN:[856..860] from)
              (NP
                (NP (NNS:[861..867] livers))
                (PP (IN:[868..870] of)
                  (NP
                    (ADJP (NN:[871..878] acetone) (HYPH:[878..879] -)
                          (VBN:[879..886] treated))
                    (NML (NNP:[887..894] Sprague) (HYPH:[894..895] -)
                         (NNP:[895..901] Dawley))
                    (NNS:[902..906] rats)))))))))
    (,:[906..907] ,)
    (NP-SBJ-1 (NN:[908..920] sulforaphane))
    (VP (VBD:[921..924] was)
      (VP (VBN:[925..930] shown)
        (S
          (NP-SBJ-1 (-NONE-:[930..930] *))
          (VP (TO:[931..933] to)
            (VP (VB:[934..936] be)
              (NP-PRD
                (NP (DT:[938..939] a) (JJ:[940..946] potent)
                    (JJ:[947..958] competitive) (NN:[959..968] inhibitor))
                (PP (IN:[969..971] of)
                  (NP (NN:[972..978] CYP2E1))))
              (PP (IN:[979..983] with)
                (NP
                  (NP (DT:[984..985] a) (NN:[986..988] Ki))
                  (PP (IN:[989..991] of)
                    (NP
                      (QP (CD:[992..996] 37.0) (SYM:[997..1000] +/-)
                          (CD:[1001..1004] 4.5))
                      (NN:[1005..1011] microM))))))))))
    (.:[1011..1012] .)))

;sentence 8 Span:1013..1140
;In  view of this result, we studied the capacity of sulforaphane to inhibit
;the  genotoxicity of N-nitrosodimethylamine (NDMA).
;[1065..1077]:substance:"sulforaphane"
;[1110..1132]:substance:"N-nitrosodimethylamine"
;[1134..1138]:substance:"NDMA"
(SENT
  (S
    (PP (IN:[1013..1015] In)
      (NP
        (NP (NN:[1017..1021] view))
        (PP (IN:[1022..1024] of)
          (NP (DT:[1025..1029] this) (NN:[1030..1036] result)))))
    (,:[1036..1037] ,)
    (NP-SBJ (PRP:[1038..1040] we))
    (VP (VBD:[1041..1048] studied)
      (NP
        (NP (DT:[1049..1052] the) (NN:[1053..1061] capacity)
          (S-1 (-NONE-:[1061..1061] *ICH*)))
        (PP (IN:[1062..1064] of)
          (NP (NN:[1065..1077] sulforaphane)))
        (S-1
          (NP-SBJ (-NONE-:[1077..1077] *))
          (VP (TO:[1078..1080] to)
            (VP (VB:[1081..1088] inhibit)
              (NP
                (NP (DT:[1089..1092] the) (NN:[1094..1106] genotoxicity))
                (PP (IN:[1107..1109] of)
                  (NP
                    (NP (NN:[1110..1132] N-nitrosodimethylamine))
                    (NP (-LRB-:[1133..1134] -LRB-) (NN:[1134..1138] NDMA)
                        (-RRB-:[1138..1139] -RRB-))))))))))
    (.:[1139..1140] .)))

;sentence 9 Span:1141..1385
;Sulforaphane at concentrations of  > 0.8 microM inhibited the mutagenicity of
;NDMA (4.4 mg/plate) in Salmonella  typhimurium strain TA100 after
;pre-incubation for 45 min with cytosol extract  from livers of Balb/c mice
;pre-treated with acetone.
;[1141..1153]:substance:"Sulforaphane"
;[1176..1181]:quantitative-value:"> 0.8"
;[1182..1188]:quantitative-units:"microM"
;[1219..1223]:substance:"NDMA"
;[1225..1228]:quantitative-value:"4.4"
;[1229..1237]:quantitative-units:"mg/plate"
;[1304..1306]:quantitative-value:"45"
;[1307..1310]:quantitative-units:"min"
;[1377..1384]:substance:"acetone"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1141..1153] Sulforaphane))
      (PP (IN:[1154..1156] at)
        (NP
          (NP (NNS:[1157..1171] concentrations))
          (PP (IN:[1172..1174] of)
            (NP
              (QP (SYM:[1176..1177] >) (CD:[1178..1181] 0.8))
              (NN:[1182..1188] microM))))))
    (VP (VBD:[1189..1198] inhibited)
      (NP
        (NP (DT:[1199..1202] the) (NN:[1203..1215] mutagenicity))
        (PP (IN:[1216..1218] of)
          (NP (NN:[1219..1223] NDMA)
            (PRN (-LRB-:[1224..1225] -LRB-)
              (NP
                (NP (CD:[1225..1228] 4.4) (NN:[1229..1231] mg))
                (PP (SYM:[1231..1232] /)
                  (NP (NN:[1232..1237] plate))))
              (-RRB-:[1237..1238] -RRB-)))))
      (PP-LOC (IN:[1239..1241] in)
        (NP
          (NML (NN:[1242..1252] Salmonella) (NN:[1254..1265] typhimurium))
          (NN:[1266..1272] strain) (NN:[1273..1278] TA100)))
      (PP-TMP (IN:[1279..1284] after)
        (NP
          (NP (AFX:[1285..1288] pre) (HYPH:[1288..1289] -)
              (NN:[1289..1299] incubation))
          (PP-TMP (IN:[1300..1303] for)
            (NP (CD:[1304..1306] 45) (NN:[1307..1310] min)))
          (PP (IN:[1311..1315] with)
            (NP
              (NP (NN:[1316..1323] cytosol) (NN:[1324..1331] extract))
              (PP (IN:[1333..1337] from)
                (NP
                  (NP (NNS:[1338..1344] livers))
                  (PP (IN:[1345..1347] of)
                    (NP
                      (NP
                        (NML (NN:[1348..1352] Balb) (SYM:[1352..1353] /)
                             (NN:[1353..1354] c))
                        (NNS:[1355..1359] mice))
                      (VP (AFX:[1360..1363] pre) (HYPH:[1363..1364] -)
                          (VBN:[1364..1371] treated)
                        (NP (-NONE-:[1371..1371] *))
                        (PP-MNR (IN:[1372..1376] with)
                          (NP (NN:[1377..1384] acetone)))))))))))))
    (.:[1384..1385] .)))

;sentence 10 Span:1386..1541
;Unscheduled DNA synthesis  induced by NDMA (33.5 microM) in mouse hepatocytes
;was inhibited in a  dose-dependent manner by sulforaphane at 0.064-20
;microM.
;[1398..1401]:substance:"DNA"
;[1424..1428]:substance:"NDMA"
;[1430..1434]:quantitative-value:"33.5"
;[1435..1441]:quantitative-units:"microM"
;[1509..1521]:substance:"sulforaphane"
;[1525..1533]:quantitative-value:"0.064-20"
;[1534..1540]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1386..1397] Unscheduled) (NN:[1398..1401] DNA)
          (NN:[1402..1411] synthesis))
      (VP (VBN:[1413..1420] induced)
        (NP (-NONE-:[1420..1420] *))
        (PP (IN:[1421..1423] by)
          (NP-LGS (NN:[1424..1428] NDMA)
            (PRN (-LRB-:[1429..1430] -LRB-)
              (NP (CD:[1430..1434] 33.5) (NN:[1435..1441] microM))
              (-RRB-:[1441..1442] -RRB-))))
        (PP-LOC (IN:[1443..1445] in)
          (NP (NN:[1446..1451] mouse) (NNS:[1452..1463] hepatocytes)))))
    (VP (VBD:[1464..1467] was)
      (VP (VBN:[1468..1477] inhibited)
        (NP-1 (-NONE-:[1477..1477] *))
        (PP (IN:[1478..1480] in)
          (NP (DT:[1481..1482] a)
            (ADJP (NN:[1484..1488] dose) (HYPH:[1488..1489] -)
                  (JJ:[1489..1498] dependent))
            (NN:[1499..1505] manner)))
        (PP (IN:[1506..1508] by)
          (NP-LGS
            (NP (NN:[1509..1521] sulforaphane))
            (PP (IN:[1522..1524] at)
              (NP
                (QP (CD:[1525..1530] 0.064) (HYPH:[1530..1531] -)
                    (CD:[1531..1533] 20))
                (NN:[1534..1540] microM)))))))
    (.:[1540..1541] .)))

;sentence 11 Span:1542..1679
;Sulforaphane was  unable to inhibit mutagenicity of sodium azide (5
;micrograms/plate), a direct  acting mutagen, in the Salmonella assay.
;[1542..1554]:substance:"Sulforaphane"
;[1594..1606]:substance:"sodium azide"
;[1608..1609]:quantitative-value:"5"
;[1610..1626]:quantitative-units:"micrograms/plate"
;[1646..1653]:substance:"mutagen"
(SENT
  (S
    (NP-SBJ-1 (NN:[1542..1554] Sulforaphane))
    (VP (VBD:[1555..1558] was)
      (ADJP-PRD (JJ:[1560..1566] unable)
        (S
          (NP-SBJ-1 (-NONE-:[1566..1566] *))
          (VP (TO:[1567..1569] to)
            (VP (VB:[1570..1577] inhibit)
              (NP
                (NP (NN:[1578..1590] mutagenicity))
                (PP (IN:[1591..1593] of)
                  (NP
                    (NP
                       (NN:[1594..1600] sodium) (NN:[1601..1606] azide)
                      (PRN (-LRB-:[1607..1608] -LRB-)
                        (NP
                          (NP (CD:[1608..1609] 5) (NNS:[1610..1620] micrograms))
                          (PP (SYM:[1620..1621] /)
                            (NP (NN:[1621..1626] plate))))
                        (-RRB-:[1626..1627] -RRB-)))
                    (,:[1627..1628] ,)
                    (NP (DT:[1629..1630] a) (JJ:[1631..1637] direct)
                        (VBG:[1639..1645] acting) (NN:[1646..1653] mutagen)))))
              (,:[1653..1654] ,)
              (PP (IN:[1655..1657] in)
                (NP (DT:[1658..1661] the) (NN:[1662..1672] Salmonella)
                    (NN:[1673..1678] assay))))))))
    (.:[1678..1679] .)))

;sentence 12 Span:1680..1877
;It was not itself genotoxic in  hepatocytes, as measured by unscheduled DNA
;synthesis, or mutagenic in the  strain of Salmonella employed and cytotoxic
;only at high concentrations (> or =  0.5 mM).
;[1752..1755]:substance:"DNA"
;[1861..1872]:quantitative-value:"> or =  0.5"
;[1873..1875]:quantitative-units:"mM"
(SENT
  (S
    (NP-SBJ (PRP:[1680..1682] It))
    (VP
      (VP (VBD:[1683..1686] was)
        (ADVP=4 (RB:[1687..1690] not))
        (NP-ADV (PRP:[1691..1697] itself))
        (ADJP-PRD=1 (JJ:[1698..1707] genotoxic))
        (PP-LOC=2 (IN:[1708..1710] in)
          (NP (NNS:[1712..1723] hepatocytes)))
        (,:[1723..1724] ,)
        (SBAR-ADV=3 (IN:[1725..1727] as)
          (S
            (NP-SBJ (-NONE-:[1727..1727] *))
            (VP (VBN:[1728..1736] measured)
              (PP-MNR (IN:[1737..1739] by)
                (NP (JJ:[1740..1751] unscheduled) (NN:[1752..1755] DNA)
                    (NN:[1756..1765] synthesis)))))))
      (,:[1765..1766] ,) (CC:[1767..1769] or)
      (VP
        (ADJP-PRD=1 (JJ:[1770..1779] mutagenic))
        (PP-LOC=2 (IN:[1780..1782] in)
          (NP
            (NP
              (NP (DT:[1783..1786] the) (NN:[1788..1794] strain))
              (PP (IN:[1795..1797] of)
                (NP (NN:[1798..1808] Salmonella))))
            (VP (VBN:[1809..1817] employed)
              (NP (-NONE-:[1817..1817] *)))))
        (SBAR-ADV=3 (-NONE-:[1817..1817] *NOT*)))
      (CC:[1818..1821] and)
      (VP
        (ADVP=4 (-NONE-:[1821..1821] *NOT*))
        (ADJP-PRD=1 (JJ:[1822..1831] cytotoxic))
        (PP (RB:[1832..1836] only) (IN:[1837..1839] at)
          (NP (JJ:[1840..1844] high) (NNS:[1845..1859] concentrations)
            (PRN (-LRB-:[1860..1861] -LRB-)
              (NP
                (QP (SYM:[1861..1862] >) (CC:[1863..1865] or)
                    (SYM:[1866..1867] =) (CD:[1869..1872] 0.5))
                (NN:[1873..1875] mM))
              (-RRB-:[1875..1876] -RRB-))))
        (PP-LOC=2 (-NONE-:[1876..1876] *NOT*))
        (SBAR-ADV=3 (-NONE-:[1876..1876] *NOT*))))
    (.:[1876..1877] .)))

;sentence 13 Span:1878..2017
;These findings suggest that inhibition of CYP2E1 by sulforaphane may  offer
;chemoprotection against carcinogenic substrates of this enzyme.
;[1920..1926]:cyp450:"CYP2E1"
;[1930..1942]:substance:"sulforaphane"
;[1991..2001]:substance:"substrates"
;[2010..2016]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ (DT:[1878..1883] These) (NNS:[1884..1892] findings))
    (VP (VBP:[1893..1900] suggest)
      (SBAR (IN:[1901..1905] that)
        (S
          (NP-SBJ
            (NP (NN:[1906..1916] inhibition))
            (PP (IN:[1917..1919] of)
              (NP (NN:[1920..1926] CYP2E1)))
            (PP (IN:[1927..1929] by)
              (NP (NN:[1930..1942] sulforaphane))))
          (VP (MD:[1943..1946] may)
            (VP (VB:[1948..1953] offer)
              (NP
                (NP (NN:[1954..1969] chemoprotection))
                (PP (IN:[1970..1977] against)
                  (NP
                    (NP (JJ:[1978..1990] carcinogenic)
                        (NNS:[1991..2001] substrates))
                    (PP (IN:[2002..2004] of)
                      (NP (DT:[2005..2009] this) (NN:[2010..2016] enzyme)))))))))))
    (.:[2016..2017] .)))

;section 14 Span:2021..2065
;PMID: 8625450 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2021..2025] PMID) (::[2025..2026] :) (CD:[2027..2034] 8625450)
        (NN:[2035..2036] -LSB-) (NNP:[2036..2042] PubMed) (::[2043..2044] -)
        (NN:[2045..2052] indexed) (IN:[2053..2056] for)
        (NNP:[2057..2065] MEDLINE-RSB-)))
